Phaseline

Companies › TG Therapeutics

TG Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 12 registered trials: 7 Phase 2, 3 Phase 3, 1 Phase 4, 1 Phase 1; Neurology, Immunology, Oncology, Psychiatry; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ublituximab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Relapsing Multiple Sclerosis; Relapsing Multiple Sclerosis (RMS); Multiple Sclerosis; Myasthenia Gravis …Jan 2027
Azercabtagene zapreleucel (azer-cel)
CAR-T cell therapy targeting CD19-expressing B cells
CD19Phase 1B-cell Mediated Autoimmune DisordersDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06680037Azercabtagene zapreleucel (azer-cel)Phase 1B-cell Mediated Autoimmune DisordersNeurologyDec 2026
NCT05877963UblituximabPhase 3Relapsing Multiple SclerosisNeurologyJan 2027
NCT04783415UblituximabPhase 2Mantle Cell LymphomaOncologyJul 2027
NCT07503873UblituximabPhase 2Multiple SclerosisNeurologyJul 2027
NCT04624633UblituximabPhase 2Chronic Lymphocytic LeukemiaOncologyJan 2028
NCT07673744UblituximabPhase 2Myasthenia GravisNeurologyJul 2028
NCT07103746UblituximabPhase 2Autoimmune DisordersImmunologyAug 2028
NCT07680946UblituximabPhase 2SchizophreniaPsychiatryDec 2028
NCT07211633UblituximabPhase 3Relapsing Multiple SclerosisNeurologyDec 2028
NCT07225361UblituximabPhase 4Multiple SclerosisNeurologyMar 2029
NCT07220252UblituximabPhase 2Relapsing Multiple SclerosisNeurologyJan 2030
NCT04130997UblituximabPhase 3Relapsing Multiple Sclerosis (RMS)NeurologyMay 2032

From the company's SEC filings

Cash and short-term investments of $557m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

MS4A1 (1) CD19 (1)

Companies with the same targets

Roche Bristol-Myers Squibb Gilead Sciences Chongqing Precision Biotech AstraZeneca ImmunityBio Amgen Allogene Therapeutics Miltenyi Biomedicine Biocad

Companies built like this

Autolus Aurinia Pharmaceuticals Sarepta Therapeutics MeiraGTx Biogen

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.